A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA

Neurology

Volumn 66, Issue 10, 2006, Pages 1470-1475

  Majamaa Voltti, K A M ^a   Winqvist, S ^a   Remes, A M ^a   Tolonen, U ^b   Pyhtinen, J ^a   Uimonen, S ^a   Karppa M ^a   Sorri, M ^a   Peuhkurinen, K ^c   Majamaa, K ^a,d  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; LACTIC ACID DERIVATIVE; PYRUVIC ACID DERIVATIVE;

ADOLESCENT; ARTICLE; ATAXIA; AUDIOMETRY; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAM; EPILEPSY; FOLLOW UP; GENE MUTATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LACTIC ACIDOSIS; LEUKOCYTE; MITOCHONDRIAL DNA DISORDER; MYOPATHY; NEUROIMAGING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCEPTION DEAFNESS; PRIORITY JOURNAL; SHORT STATURE; STROKE; ADULT; ALLELE; BLOOD; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; FINLAND; GENETICS; GLUCOSE BLOOD LEVEL; MALE; MELAS SYNDROME; METABOLISM; MIDDLE AGED; MORTALITY; MOSAICISM; MUSCLE MITOCHONDRION; NEUROPSYCHOLOGICAL TEST; POINT MUTATION;

ADULT; ALLELES; BLOOD GLUCOSE; COGNITION DISORDERS; DIABETES MELLITUS; DISEASE PROGRESSION; DNA, MITOCHONDRIAL; ELECTROCARDIOGRAPHY, AMBULATORY; ELECTROENCEPHALOGRAPHY; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEARING LOSS, SENSORINEURAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LACTATES; MALE; MELAS SYNDROME; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MOSAICISM; NEUROPSYCHOLOGICAL TESTS; POINT MUTATION; PYRUVATES;

EID: 33745350363     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000216136.61640.79     Document Type: Article

References (44)

1. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999;283:1482-1488.
2. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997;120:1713-1721.
3. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. MELAS and MERRF. The relationship between maternal mutation load and the frequency of clinically affected offspring. Brain 1998;121:1889-1894.
4. Kärppä M Herva R, Moslemi AH, Oldfors A, Kakko S, Majamaa K. Spectrum of myopathic findings in 50 patients with the 3243A>G mutation in mitochondrial DNA. Brain 2005;128:1861-1869.
5. Anan R, Nakagawa M, Miyata M, et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 1995;91:955-961.
6. Vilarinho L, Santorelli FM, Rosas MJ, Tavares C, Melo-Pires M, Di-Mauro S. The mitochondrial A3243G mutation presenting as severe cardiomyopathy. J Med Genet 1997;34:607-609.
7. Majamaa-Voltti K, Peuhkurinen K, Kortelainen ML, Hassinen IE, Majamaa K. Cardiac abnormalities in patients with mitochondrial DNA mutation 3243A>G. BMC Cardiovasc Disord 2002;2:12.
8. Okajima Y, Tanabe Y, Takayanagi M, Aotsuka H. A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Heart 1998;80:292-295.
9. Damian MS, Hertel A, Seibel P, et al. Follow-up in carriers of the 'MELAS' mutation without strokes. Eur Neurol 1998;39:9-15.
10. Lien LM, Lee HC, Wang KL, Chiu JC, Chiu HC, Wei YH. Involvement of nervous system in maternally inherited diabetes and deafness (MIDD) with the A3243G mutation of mitochondrial DNA. Acta Neurol Scand 2001;103:159-165.
11. Uimonen S, Moilanen JS, Sorri M, Hassinen IE, Majamaa K. Hearing impairment in patients with 3243A->G mtDNA mutation: phenotype and rate of progression. Hum Genet 2001;108:284-289.
12. Majamaa K, Mollanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447-454.
13. Guy E. Clinical global impressions. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. Rockville: National Institute of Mental Health, 1976:218-222.
14. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
15. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
16. Rankin J. Cerebral vascular accidents in patients over the age of 60. III. Diagnosis and treatment. Scott Med J 1957;2:254-268.
17. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation, 1981.
18. Wechsler D. A standardized memory test for clinical use. J Psychol 1945;87-95.
19. Christensen AL. Luria's neuropsychological investigation. Copenhagen: P.J. Schidts Boktrykkeri, 1975.
20. Benton AL. Benton Revised Visual Retention Test, 4th ed. Helsinki: Psykologien Kustannus OY, 1978.
21. Reitan R. The relation of the trail making test to organic brain damage. J Consult Psychol 1955;393-394.
22. Lezak M. Neuropsychological assessment. New York: Oxford University Press, 1995.
23. Kessels RP, Postma A, Kappelle LJ, de Haan EH. Spatial memory impairment in patients after tumour resection: evidence for a double dissociation. J Neurol Neurosurg Psychiatry 2000;69:389-391.
24. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Sub-committee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
25. Devereux RB, Casale PN, Kligfield P, et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986;57:1388-1393.
26. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
27. Feigenbaum H. Echocardiographic measurements and normal values. Echocardiography, 5th ed. Philadelphia: Lea & Febiger, 1994:658.
28. Feigenbaum H. Mitral valve flow. Echocardiography. 5th ed. Philadelphia: Lea & Febiger, 1994:188.
29. Laffey PA, Peyster RG, Nathan R, Haskin ME, McGinley JA. Computed tomography and aging: results in a normal elderly population. Neuroradiology 1984;26:273-278.
30. Rezek DL, Morris JC, Fulling KH, Gado MH. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987;37:1365-1368.
31. Parving ANV. Guidelines for description of inherited hearing loss. J Audiological Med 1995;2-4.
32. Liu X, Xu L. Nonsyndromic hearing loss: an analysis of audiograms. Ann Otol Rhinol Laryngol 1994;103:428-433.
33. European Working Group on Genetics of Hearing Impairment. European Commission Directorate. Biomedical and Health Research Programme (HEAR). Brussels: European Commission, 1996.
34. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-20.
35. Kobayashi Y, Momoi MY, Tominaga K, et al. A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem Biophys Res Commun 1990;173:816-822.
36. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-330.
37. Dubeau F, De SN, Zifkin BG, Arnold DL, Shoubridge EA. Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol 2000;47:179-185.
38. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101:2271-2276.
39. Carugo S, Giannattasio C, Calchera I, et al. Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with type 1 diabetes mellitus. J Hypertens 2001;19:1675-1680.
40. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab 1998;83:4284-4288.
41. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218.
42. Klopstock T, Jaksch M, Gasser T. Age and cause of death in mitochondrial diseases. Neurology 1999;53:855-857.
43. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004;114:925-931.
44. Okhuijsen-Kroes EJ, Trijbels JM, Sengers RC, et al. Infantile presentation of the mtDNA A3243G tRNA(Leu (UUR)) mutation. Neuropediatrics 2001;32:183-190.